Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2011 April 15.
Published in final edited form as:
PMCID: PMC2955801

Unique DNA methylation patterns distinguish non-invasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue


Urothelial cancer (UC) develops along two different genetic pathways, resulting in non-invasive or invasive tumors. However, it is unknown whether there are also different epigenetic pathways in UC. UC is also characterized by a high rate of recurrence and the presence of a field defect has been postulated. In this study, we compared the DNA methylation patterns between non-invasive and invasive UC, and the DNA methylation patterns in normal-appearing urothelium from bladders with cancer to urothelium from cancer-free bladders. We used the Illumina GoldenGate methylation assay at 1,370 loci in 49 non-invasive urothelial tumors, 38 invasive tumors with matched normal-appearing urothelium, and urothelium from 12 age-matched urothelial cancer-free patients. We found a distinct pattern of hypomethylation in the non-invasive tumors and widespread hypermethylation in the invasive tumors, confirming that the two pathways differ epigenetically in addition to genetically. We also found that 12% of the loci were hypermethylated in apparently normal urothelium from bladders with cancer, indicating an epigenetic field defect. X-chromosome inactivation analysis indicated that this field defect did not result in clonal expansion but occurred independently across the urothelium of bladders with cancer. The hypomethylation present in non-invasive tumors may counter-intuitively provide a biological explanation for the failure of these tumors to become invasive. In addition, an epithelium-wide epigenetic defect in bladders with cancer may contribute to a loss of epithelial integrity and create a permissible environment for tumors to arise.


Urothelial cancer (UC) is the 5th most commonly diagnosed cancer in the US and has a high rate of recurrence, making it one of the most burdensome cancers to treat. UC is, however, a fascinating disease to study from the scientific standpoint because several details of the molecular pathology are now understood. There appears to be two pathways to UC in which distinct genetic alterations occur. Most patients who present with UC have low-stage non-invasive tumors (Ta-T1) that are normally treated by resection and rarely progress to form invasive tumors (T2-T4). The low-stage tumors often have FGFR3 mutations (1) together with chromosome 9 aberrations (2, 3). In contrast, flat carcinomas in situ frequently have TP53 mutations in addition to chromosome 9 deletions (4) and these tumors progress to become muscle invasive, acquiring RB1 aberrations (5), and DNA hypermethylation (6).

DNA methylation, nucleosome positioning, and histone modifications are epigenetic processes that heritably change gene expression without altering the DNA sequence (7). DNA methylation of cytosine residues occurs in the context of CpG dinucleotides. Most unmethylated CpGs are found in GC-rich sequences referred to as CpG islands. Approximately 40~50% of human genes are associated with CpG islands (8) and it has been shown repeatedly that methylation of the CpG sites within these promoters can effectively and heritably silence genes. The progressive increase in de novo methylation of CpG islands in urothelial carcinoma cells suggests that epigenetic gene silencing is involved in the development of UC (6, 913).

Successes in the clinic have opened up the era of epigenetic therapy in which the goal is to reactivate genes silenced inappropriately during carcinogenesis (14). The advantage of using epigenetic therapy to target defects in DNA methylation is that, unlike mutations in the DNA sequence, these alterations are reversible. While DNA methylation inhibitors are effective in treating cancers of the blood, their efficacy in treating solid tumors remains controversial. We have demonstrated in mice that DNA methylation inhibitors can slow the growth of tumor xenografts (15) and prevent formation of tumor precursors (16), as well as reduce DNA methylation levels in normal tissues. Therefore it is possible that systemic treatment of humans with these same drugs will affect aberrant DNA methylation in a variety of tissues and will be useful for treating and preventing solid tumors such as those of the bladder. However, the epigenetic alterations in urothelial tumorigenesis must first be elucidated to determine whether they provide useful therapeutic targets for epigenetic therapy. An ideal therapy for UC would address many of its unique aspects, such as treating both non-invasive and invasive tumors even though they develop via two separate molecular pathways and reducing the high frequency of recurrences.

The biological basis for the high rate of recurrence for urothelial tumors remains unknown, although the presence of a field defect has been postulated (9). A field defect is an area of tissue that is predisposed to undergo transformation and has been proposed as an underlying mechanism of tumor recurrences and multifocality. It remains unclear whether such premalignant changes in an affected organ are due to expansion of a single cell with a growth advantage or due to a generalized defect. DNA methylation has been shown to be involved in field defects in other cancers (1720), highlighting the possible role of epigenetic alterations in the development of cancer. By conducting high-throughput DNA methylation analysis on urothelial tumors, corresponding normal-appearing tissues, and tissue from cancer-free bladders we found DNA hypermethylation in normal appearing tissues from bladders with cancer, supporting the presence of an epigenetic field defect. We also revealed that non-invasive tumors and invasive tumors arise via distinct epigenetic pathways. Non-invasive tumors display a unique hypomethylated phenotype, which may counter-intuitively provide a biological explanation for the failure of these tumors to become invasive and life threatening. Therefore, epigenetic therapy may be useful for targeting tumors and also to help prevent future recurrences by reversing premalignant changes before a new tumor forms.


Tissue Samples and DNA/RNA Isolation

Tumor tissue samples were collected from the patients undergoing cystectomy or TURBT (Transurethral Resection of Bladder Tumor) for UC. Twelve samples of normal urothelium were obtained from five patients undergoing radical prostatectomy for prostate cancer (aged from 50 to 80) and seven autopsy patients aged from 34 to 82 (five from non-cancer related deaths and the remaining from deaths due to cancers other than bladder). We also included 49 non-invasive urothelial tumors (Ta-T1), 38 invasive tumors (T2-T4), and 34 normal-appearing tissues from patients that were having their entire bladders removed. See Table 1 for a summary of the clinicopatholgical information on the patients from which tumors were collected and Supplemental Table 1 for more detailed information. All of these collections took place at Norris Cancer Hospital in IRB-approved protocols with patients’ consent. Hematoxylin and eosin (H&E) sections marked with the location of the corresponding normal urothelium or tumor were used to guide in microdissection. DNA was bisulfite treated as previously described (21). Total RNA extraction was done using an RNAeasy Micro Kit (Qiagen, Crawley, UK. RNA was reverse-transcribed as previously described (11).

Table 1
Clinicopathological characteristics of the study population

Illumina GoldenGate Methylation Assay

Bisulfite conversion of 2–4 ug of genomic DNA was achieved through use of the EZ DNA Methylation-Gold kit (Zymo Research, Orange, CA). The samples were interrogated using the Illumina GoldenGate methylation cancer panel I, and measurements were computed using Illumina BeadStudio Software. A beta (β) value of 0–1.0 was reported for each CpG site signifying percent methylation from 0% to 100%, respectively. β-values were calculated by subtracting background using negative controls on the array and taking the ratio of the methylated signal intensity to the sum of both methylated and unmethylated signals plus a constant of 100. Measurements with detection P-values greater than 0.05 were marked as missing.

Validation of GoldenGate DNA Methylation Results

Pyrosequencing was also performed as described previously (22). Briefly, bisulfite-converted DNA was PCR-amplified using a biotin-labeled 3′ primer to enable purification and denaturation of the product by Streptavidin-Sepharose beads. This was followed by annealing of a sequencing primer to the single-stranded PCR product. Pyrosequencingwas performed using the PSQ HS96 Pyrosequencing System and the degree of DNA methylation was expressed for each DNA locus aspercentage methylated cytosines over the sum of methylated andunmethylated cytosines.

Bisulfite Sequencing and X-chromosome Inactivation Analysis

To analyze the DNA methylation status of individual DNA molecules, bisulfite PCR fragments were cloned into the pCR2.1 vector using the TOPO-TA cloning kit (Invitrogen, Carlsbad, CA). Individual colonies were screened for the insert and the region of interest was sequenced using M13 primers. Bisulfite sequencing was performed on a region of the X-chromosome with an A/T single nucleotide polymorphism (SNP) (rs4826507) and six CpG sites that are differentially methylated between the active and inactive X chromosomes (23), allowing for the simultaneous identification of which X-chromosome was being interrogated and its activation status.

Statistical Analysis

Probes that were missing measurements in 10 or more samples were excluded from the statistical analysis. Average linkage hierarchical clustering using Euclidean distance was employed to group the probes with similar DNA methylation patterns for all the samples.

The Wilcoxon Rank Sum Test was used to evaluate the statistical significance of the separate comparisons between normal samples and the invasive tumors, non-invasive tumors, and normal-appearing adjacent tissue. To account for testing three comparisons for each probe, we multiplied each P-value by three (Bonferroni correction) prior to applying a false-discovery rate (FDR) adjustment across all probes for each pair-wise comparison. We used the Benjamini and Hochberg method (24) to control the FDR, using a threshold of 5% (two-sided) to select differentially methylated probes (hyper- and hypomethylation).

Gene expression data were obtained from GeneChiPs (Affymetrix) using U133A human Gene-Chips containing 22,283 probes representing known genes and expression sequence tag (Affymetrix) (25). The differentially expressed genes were identified by comparing 105 urothelial tumors: 33 non-invasive (Ta-T1), 72 invasive lesions (T2-T4), and 52 normal urothelium, differential expression was evaluated using the signal as the main response measure, extracted from each gene on every sample, as determined by default setting of the MAS 5.0 (25). The gene expression and DNA methylation measurements of a gene were linked by the NCBI gene identifier. To carry out concordance analysis between the DNA methylation and gene expression, we first selected the unique DNA methylation probe from each gene that is closest to the Transcription Start Site (TSS) based on the NCBI gene identifier. A total of 784 genes were selected. Genes with multiple expression probe sets were classified by the probe set with the minimum p-value. We then categorized the genes into nine groups based on the DNA methylation and gene expression measurements: hypermethylation versus hypomethylation versus no significant DNA methylation changes; decreased expression versus increased expression versus no significant gene expression changes. We used chi-square statistics on 4 degrees of freedom to test for associations between DNA methylation and gene expression. To visualize these nine groups of genes, we employed the starburst plot using the FDR adjusted P-values for differences in the DNA methylation and gene expression (26).


Non-invasive urothelial tumors have a distinct pattern of hypomethylation

We used the Illumina GoldenGate platform to conduct a large-scale analysis of DNA methylation in tissues from cancer-free urothelial samples (N), corresponding normal-appearing tissues from bladders with cancer (CN), and urothelial tumors at 1,370 autosomal loci (784 genes) (Figure 1 and Supplementary Table 1). We included 49 non-invasive urothelial tumors (Ta-T1) and 38 invasive tumors (T2-T4) (Table 1). Progressive hypermethylation in invasive cancer has been widely documented. As expected, when we compared the two types of tumors to the 12 samples of urothelium obtained from patients without UC (Figure 1 and Figure 2, A), more loci were hypermethylated in invasive tumors (526, 38 %) than in non-invasive tumors (132, 10%), with the majority of those in the non-invasive tumors (117/132, 89%) overlapping with the invasive tumors (p<0.0001 by Fisher’s exact test). Most of the hypermethylated loci were located in the context of CpG islands (Figure 1 and Figure 2, B). Interestingly, we also found a distinct pattern of hypomethylation in non-invasive (Ta-T1) tumors compared to both normal urothelium and invasive tumors (Figure 2, A). A substantial number of probes (217, 16%) were hypomethylated only in the non-invasive tumors compared to those only hypomethylated in invasive tumors (41, 3%) (McNemar’s p < 0.001), in addition to those loci hypomethylated in both types (253, 18%). Most of the hypomethylated loci were located outside of CpG islands (Figure 1 and Figure 2, B). Confirmation of five identified hypermethylated loci and five hypomethylated loci with Pyrosequencing is shown in Supplementary Figure 1. This distinct pattern of hypomethylation in the non-invasive tumors suggests the two separate molecular pathways to non-invasive or invasive urothelial tumors differ epigenetically as well as genetically.

Figure 1
Supervised cluster analysis of bladder samples at 1,370 loci (784 genes) using the Illumina GoldenGate methylation assay. N (n=12) represents normal tissue from patients without UC, CN (n=34) represents corresponding normal-appearing tissue from UC patients, ...
Figure 2
A) Venn diagram of the overlap of hypermethylated and hypomethylated loci. The hypermethylated and hypomethyated cancer-specific loci were determined using three separate comparisons of tissue from UC patients (CN, Ta-T1, and T2-T4) to 12 N samples (5% ...

Gene promoter DNA methylation inversely correlates with expression in urothelial tumors

In order to determine whether the aberrantly hypermethylated and hypomethylated loci might play a functional role in tumorigenesis we compared our DNA methylation data to already available gene expression data (25) (Figure 2, C). We found that differential DNA methylation was associated with differential gene expression for both invasive and superficial tumors (p<0.0001 and p = 0.001, respectively). A substantial number of hypermethylated genes correlated with decreased gene expression in the non-invasive tumors (37 observed compared to 30 expected, ratio = 1.24, p = 0.11) and in the invasive tumors (117 observed compared to 92 expected, ratio = 1.28, p < 0.0001) when compared to normal urothelium. We also found that similar ratios of observed to expected counts for hypomethylated genes showing overexpression relative to the normal tissues in both the non-invasive (101 observed compared to 83 expected, ratio = 1.21, p = 0.004) and invasive tumors (56 observed compared to 45 expected, ratio = 1.24, p = 0.04), indicating that both DNA hypermethylation and hypomethylation of gene promoters correlates with gene expression changes in tumors. It should be noted that while integrating DNA methylation and gene expression data from the same specimens is ideal; the correlations from these independent data sets are biologically intriguing in elucidating the role of aberrant DNA methylation on gene expression alterations in UC.

Urothelial cancers have a widespread epigenetic field defect

In addition to the widespread alterations of DNA methylation in urothelial tumors we also discovered 169 probes spanning 155 unique gene regions that were aberrantly methylated in normal-appearing tissues taken at least 5 cm away from the site of their corresponding invasive tumor (Figure 2, A). The majority of these probes were also identified as DNA hypermethylated in invasive tumors (128/155, 83%, p<0.0001 by Fisher’s exact test) and a smaller portion in non-invasive tumors (39, 25%, p<0.0001 by Fisher’s exact test) (Figure 2, A). Only 18 genes (2%) were found to be hypomethylated, indicating that aberrant hypermethylation may constitute the majority of epigenetic defects present in the urothelium. In order to rule out potential contamination of corresponding normal tissues with tumor cells, we also performed unsupervised hierarchical clustering analysis (Supplementary Figure 2). In general, corresponding normal tissues cluster together and tumors cluster together with no clustering of tissues from a single individual, thereby clearly ruling out the potential contamination. These hypermethylated loci may provide markers for the identification of individuals at risk for developing UC, as they are only altered in bladders with cancer.

Further examination of DNA methylation changes at a few of these loci reveals a clear increase of methylation in corresponding normal-appearing tissues, including at ZO2 (Zona occludens 2 or TJP2) (Figure 3, A), a tight junction binding protein, MYOD1, and CDH13 (H-cadherin) (Supplementary Figure 3). In addition to serving as biomarkers, the DNA methylation changes found at these loci may have functional significance. Examining the expression of ZO2 in the same clinical samples revealed that while it was expressed in normal urothelium, it showed reduced expression in the corresponding normal-appearing tissue and even less in tumors, indicating that DNA hypermethylation of ZO2 is associated with reduced expression (Figure 3, A). Bisulfite sequencing confirmed the absence of DNA methylation in normal urothelium from a bladder cancer-free patient, a low level of DNA methylation in corresponding normal-appearing tissue, and a high level of DNA methylation in the urothelial tumor from the same patient (Figure 3, B).

Figure 3
Aberrant DNA hypermethylation at ZO2 in corresponding normal-appearing tissues reveals the presence of a field defect in bladders with cancer. A) DNA methylation data from the Illumina GoldenGate assay performed on normal urothelium from patients without ...

In order to determine the full extent of DNA hypermethylation in histologically normal tissue and to attempt to elucidate the mechanism driving such alterations, we collected a series of tissue samples taken from various distances away from tumors in five primary bladder tissues (Figure 3, C). We found DNA hypermethylation of ZO2 across bladders with cancer when compared to the average level of ZO2 DNA methylation in normal urothelium from urothelial cancer-free patients, indicating the presence of a widespread epigenetic field defect in bladders with cancer (Figure 3, D). ZO2 methylation was reduced by treatment with the DNA methylation inhibitor 5-aza-2′deoxycytidine (5-aza-CdR) in UC cell lines, leading to re-expression of the gene (data not shown). Taken together these results suggest that epigenetic therapy, in addition to having the potential to treat urothelial tumors, may also be able to prevent cancer by reversing premalignant defects in bladders.

The epigenetic field defect in bladders is not due to clonal expansion

To address whether the widespread epigenetic field defect found in bladders with cancer is due to clonal expansion across the bladder or a generalized epigenetic alteration, we first sequenced DNA from tumors of these same five patients for one of the earliest genetic alterations in UC, FGFR3 mutations (27, 28). FGFR3 was mutated only in the tumor samples and not in any of the corresponding normal samples (#6519 at S249C and #6671 at F384I), similar to recent results from Otto et al. (29). Since it is possible that clonal expansion could have occurred before the FGFR3 mutation was acquired, we also examined the pattern of X chromosome inactivation in the series of samples taken from the two female patients, #6522 and #6671. X-inactivation patterns are permanent marks of clonality. By conducting bisulfite sequencing on a region that contains a single nucleotide polymorphism (SNP) which is differentially methylated between the active and inactive X-chromosomes we found that a random pattern of X-inactivation was maintained across these bladders (Figure 4, A). In addition, previous work with a different set of bladder specimens has shown that clonality is maintained across the urothelium of female patients with UC (30). These results suggest that the generalized epigenetic defect does not give rise to a clonal dominance of the histologically normal cells but may provide a permissive environment either for the emergence of tumor clones containing genetic mutations or the seeding or migration of tumor cells once they arise (Figure 4, B).

Figure 4
X-inactivation patterns reveal that the urothelium of two female patients with UC remains polyclonal. A) Bisulfite sequencing was performed on a region located on the X-chromosome with an A/T SNP (rs4826507). This SNP is located within an exonic region ...

Genes hypermethylated in corresponding normal-appearing tissues may contribute to tumorigenesis

Since a large number of loci appear to become hypermethylated independently in both corresponding normal-appearing tissues and tumors, it is possible that these loci are either predisposed to undergo aberrant hypermethylation or contribute to tumorigenesis. It has been recently revealed that polycomb repressive complex 2 (PRC2) targets in embryonic stem cells are predisposed to undergo hypermethylation in cancer (3133). As shown in Figure 2, B, hypermethylated loci show enrichment for CpG islands. Moreover, we found that 47% of loci that were hypermethylated in the corresponding normal-appearing tissues were PRC2 targets (Figure 1 and Figure 5). This is higher than the number of loci found in the non-invasive (40%) and invasive tumors (36%), indicating that PRC2 targets are predisposed to undergo DNA hypermethylation in premalignant tissues as well as tumors. These methylated loci may contribute to tumorigenesis, as 50 of the 155 genes (32%) that are hypermethylated in the corresponding normal-appearing tissues also show downregulated gene expression levels in tumors.

Figure 5
Hypermethylated loci are enriched in Polycomb (PcG) targets. The majority of loci hypermethylated in corresponding normal-appearing tissues and tumor tissues are PcG targets, in contrast to the hypomethylated loci.


DNA methylation changes are involved in both the initiation of carcinogenesis and progression. We have demonstrated genome-scale alterations in DNA methylation patterns in urothelial tumors and also normal-appearing tissues in bladders with cancer. We also found that hypomethylation of non-CpG island regions seems to be preferentially associated with low stage Ta-T1 disease providing additional molecular evidence that there are two distinct molecular pathways to carcinoma of the bladder (4). Interest in the field of DNA methylation and cancer was originally spurred by early observations that tumors were often hypomethylated relative to normal tissues (34), the majority of which was assumed to occur at repetitive elements. It has been suggested that such hypomethylation could lead to genomic instability and contribute to the tumor phenotype (35, 36).

A systematic analysis of DNA methylation of various types of repetitive elements in urothelial tumors revealed that both Sat-α and LINE-1 elements are significantly hypomethylated (37). We have recently revealed one consequence of hypomethylation of LINE-1 elements in UC is the aberrant activation of transcripts of nearby genes (38). However, while LINE-1 promoters contain a small CpG island, the relationship between DNA methylation of non-CpG islands and expression remains controversial and underexplored even though approximately 45% of all human genes have promoters that are not located within CpG islands (39). DNA hypomethylation associated with increased gene expression has been reported in several studies (40, 41). We have recently confirmed a correlation between increased expression and hypomethylation at non-CpG island promoters in prostate cancer cell lines (32). In addition, it is possible that lower levels of DNA methylation may be related to a less malignant phenotype. For instance, when expression of the DNA methyltransferase Dnmt1 is reduced in ApcMin/+ mice, fewer intestinal tumors occur but more early intestinal lesions form, supporting opposing effects of DNA hypomethylation initiating lesions but suppressing further progression (42).

One of the most clinically relevant questions in tumor biology is why some tumors grow and progress while others remain quiescent (43). The high incidence of in situ tumors discovered during autopsies indicates that there is a rarely occurring additional step required for a tumor to become life threatening (43). Such a step has been postulated to include an angiogenic switch (43) or alterations in the stroma (44). Our results suggest that a switch to accumulating DNA hypermethylation may be involved, such as could be caused by overexpression of DNA methyltransferases (45).

We have also revealed that the urothelium in bladders with cancer is no longer “normal”. Instead, the urothelium in these diseased bladders has undergone widespread epigenetic alterations mainly consisting of aberrant hypermethylation. Our findings support a field-cancerization model where independent events occur across the urothelium resulting in a field defect that is polyclonal (Figure 4, B). The presence of an epithelial-wide defect in bladders with tumors is quite astounding. In contrast to work in other organs such as colon (18), esophagus (17), breast (19), and stomach (20), we found no dependency on the distance from the tumor. This significant difference in the pathogenesis of UC is also supported by the unique characteristics of tumor multifocality and a tendency to recur. The most likely underlying cause is that the urothelium is uniformly exposed to carcinogenic compounds excreted in the urine, and once a tumor forms, it can be assumed that the entire urothelium has been exposed to critical levels of carcinogens (45). It is also possible that the presence of the tumor itself leads to epigenetic alterations across the bladder. We observed that 83% of the hypermethylated loci found in the corresponding urothelium were also found in invasive tumors. Given such a high degree of similarity between the two tissues, we believe the most likely explanation is that these tissues are at two different steps in the tumorigenic pathway.

While the alterations in DNA methylation that occur across the entire urothelium do not directly confer a growth advantage since polyclonality of the urothelium is maintained, they may still have functional significance. The role of the tight junction binding protein ZO2 in cancer has not been studied in depth, but expression of other components of tight junctions is frequently altered in cancer, with loss of expression leading to increased cell motility and invasiveness. Increased DNA methylation of MYOD1 has previously been shown to be associated with oncogenic transformation (46). CDH13 has previous been found to be hypermethylated in premalignant gastric tissue (47) and loss of expression is associated with increased invasion in melanocytes (48). We identified a total of 72 genes as hypermethylated in corresponding normal-appearing tissues and associated with down-regulation in tumors. Taken together, the DNA methylation at these and other loci in apparently normal urothelium may contribute to a loss of epithelial integrity across the entire bladder. Such an epithelial-wide defect could allow for a more permissible environment for the growth of newly mutated cells.

One limitation of our study is that we are unable to determine whether the widespread field defect identified in bladders with invasive tumors is also present in bladders with non-invasive tumors. All of the corresponding normal-appearing tissues that we collected were from patients that were having their entire bladders removed. Treatment of non-invasive urothelials tumors usually involves surgical excision of the tumor and does not result in the collection of additional normal-appearing tissue. Therefore, since we have found that non-invasive and invasive urothelial tumors appear to undergo two separate epigenetic pathways to tumorigenesis we cannot rule out that the generalized epigenetic defect we have uncovered is specific to bladders with invasive tumors.

In summary, urothelial tumors develop along two separate molecular pathways that differ both genetically and epigenetically. A generalized epigenetic defect exists across bladders with cancer that is not due to clonal expansion. Transurethral resection of urothelial tumors leaves behind large areas of epigenetically altered urothelium, possibly contributing to the high level of recurrence of UC. Fortunately, these hypermethylated loci may provide valuable biomarkers that have the potential to significantly impact the diagnosis and treatment of UC. Such alterations can be reversed by DNA methylation inhibitors in cell culture (49), mouse models (15), and white blood cells in humans (50). Therefore it is possible that DNA methylation inhibitors may have an impact at all stages of bladder tumorigenesis: reversing premalignant epigenetic changes to prevent tumor formation or recurrence, preventing non-invasive tumors from becoming more aggressive, and inducing invasive tumors to become less malignant. In addition, the bladder may be an ideal organ for local treatment and hence avoiding systemic side-effects and highest local efficacy.

Supplementary Material




This work was supported by the National Institute of Health (R01 CA 124518 to G. L. and R01 CA 83867 to P.A.J.).


1. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nature Genetics. 1999;23:18–20. [PubMed]
2. Tsai YC, Nichols PW, Hiti AL, Williams Z, Skinner DG, Jones PA. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Research. 1990;50:44–7. [PubMed]
3. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene. 1993;8:1083–5. [PubMed]
4. Spruck CH, III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Research. 1994;54:784–8. [PubMed]
5. Cairns P, Proctor AJ, Knowles MA. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene. 1991;6:2305–9. [PubMed]
6. Salem C, Liang G, Tsai YC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Research. 2000;60:2473–6. [PubMed]
7. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature. 2004;429:457–63. [PubMed]
8. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304–51. [PubMed]
9. Friedrich MG, Chandrasoma S, Siegmund KD, et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur J Cancer. 2005;41:2769–78. [PubMed]
10. Salem CE, Markl ID, Bender CM, Gonzales FA, Jones PA, Liang G. PAX6 methylation and ectopic expression in human tumor cells. Int J Cancer. 2000;87:179–85. [PubMed]
11. Friedrich MG, Weisenberger DJ, Cheng JC, et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 2004;10:7457–65. [PubMed]
12. Byun HM, Wong HL, Birnstein EA, Wolff EM, Liang G, Yang AS. Examination of IGF2 and H19 loss of imprinting in bladder cancer. Cancer Res. 2007;67:10753–8. [PubMed]
13. Wolff EM, Liang G, Cortez CC, et al. RUNX3 Methylation reveals that Bladder Tumors are Older in Patients with a History of Smoking. Cancer Res. 2008;68:6208–14. [PMC free article] [PubMed]
14. Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50. [PubMed]
15. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399–409. [PubMed]
16. Yoo CB, Chuang JC, Byun H, et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res (Phila Pa) 2008;1:233–40. [PubMed]
17. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Cancer Res. 2000;60:5021–6. [PubMed]
18. Shen L, Kondo Y, Rosner GL, et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst. 2005;97:1330–8. [PubMed]
19. Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res. 2006;12:6626–36. [PubMed]
20. Niwa T, Tsukamoto T, Toyoda T, et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 70:1430–40. [PubMed]
21. Gonzalgo ML, Liang G. Methylation-sensitive single-nucleotide primer extension (Ms-SNuPE) for quantitative measurement of DNA methylation. Nat Protoc. 2007;2:1931–6. [PubMed]
22. Bollati V, Baccarelli A, Hou L, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 2007;67:876–80. [PubMed]
23. Hellman A, Chess A. Gene body-specific methylation on the active X chromosome. Science. 2007;315:1141–3. [PubMed]
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological) 1995;57:289–300.
25. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 2006;24:778–89. [PubMed]
26. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. Cancer Cell. 2010;17:510–22. [PMC free article] [PubMed]
27. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955–9. [PubMed]
28. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002;198:245–51. [PubMed]
29. Otto W, Denzinger S, Bertz S, et al. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. Int J Cancer. 2009;125:2205–8. [PubMed]
30. Tsai YC, Simoneau AR, Spruck CH, 3rd, et al. Mosaicism in human epithelium: macroscopic monoclonal patches cover the urothelium. J Urol. 1995;153:1697–700. [PubMed]
31. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157–8. [PubMed]
32. Gal-Yam EN, Egger G, Iniguez L, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proceedings of the National Academy of Sciences USA. 2008;105:12979–84. [PubMed]
33. Kondo Y, Shen L, Cheng AS, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40:741–50. [PubMed]
34. Riggs AD, Jones PA. 5-methylcytosine, gene regulation, and cancer. Advances in Cancer Research. 1983;40:1–30. [PubMed]
35. Hsieh CL, Jones PA. Meddling with methylation. Nature Cell Biology. 2003;5:502–4. [PubMed]
36. Estecio MR, Gharibyan V, Shen L, et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One. 2007;2:e399. [PMC free article] [PubMed]
37. Choi SH, Worswick S, Byun HM, et al. Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int J Cancer. 2009;125:723–9. [PubMed]
38. Wolff WM, Byun H, Han H, et al. Hypomethylation of a LINE-1 Promoter Activeates an Alternate Transcript of the MET Oncogene in Bladder with Cancer. PLoS Genetics. 2010;6:e1000917. [PMC free article] [PubMed]
39. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proceedings of the National Academy of Sciences USA. 2002;99:3740–5. [PubMed]
40. Sato N, Maitra A, Fukushima N, et al. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Research. 2003;63:4158–66. [PubMed]
41. Eckhardt F, Lewin J, Cortese R, et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet. 2006;38:1378–85. [PMC free article] [PubMed]
42. Yamada Y, Jackson-Grusby L, Linhart H, et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci U S A. 2005;102:13580–5. [PubMed]
43. Folkman J, Kalluri R. Cancer without disease. Nature. 2004;427:787. [PubMed]
44. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839–49. [PubMed]
45. Kanai Y. Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol Int. 2008;58:544–58. [PubMed]
46. Rideout WM, 3rd, Eversole-Cire P, Spruck CH, 3rd, et al. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol Cell Biol. 1994;14:6143–52. [PMC free article] [PubMed]
47. Yamamoto E, Toyota M, Suzuki H, et al. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev. 2008;17:2555–64. [PubMed]
48. Kuphal S, Martyn AC, Pedley J, et al. H-cadherin expression reduces invasion of malignant melanoma. Pigment Cell Melanoma Res. 2009;22:296–306. [PubMed]
49. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85–93. [PubMed]
50. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 2006;66:5495–503. [PubMed]